Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial)

Granados-Montiel et al., BMJ Open, doi:10.1136/bmjopen-2020-045190, ELEVATE, NCT04340349
Jun 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19hcq.org
Estimated 214 participant HCQ + bromhexine prophylaxis RCT with results not reported over 2 years after estimated completion.
38 HCQ RCTs have results missing long after expected Abayomi, Abu-Helalah, Ajili, Al Ansari, Aston, Borrie, Burney, Butler, Chauffe, Connor, El-Sherbiny, Farooq, Gagneux-Brunon, Genton, Ghanem-Zoubi, González, Granados-Montiel, Gül, Hawari, James, Kara, Kim, Levi, Mežnar, Moraes, Morales-Asencio, Mordmüller, Nanni, Niriella, Okasha, Pellegrini, Pineda, Sarwar, Sarwar (B), Sow, Treluyer, WellStar, White
The trials report a total of 25,399 patients, with 12 trials having actual enrollment of 8,139, and the remainder estimated.
Study covers bromhexine and HCQ.
Granados-Montiel et al., 30 Jun 2021, Double Blind Randomized Controlled Trial, placebo-controlled, Mexico, peer-reviewed, this trial uses multiple treatments in the treatment arm (combined with bromhexine) - results of individual treatments may vary, trial NCT04340349 (history) (ELEVATE). Contact: juliogram@gmail.com.
This PaperHCQAll
New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial)
Dr Julio Granados-Montiel, Eric Hazan-Lasri, Rafael Franco-Cendejas, Tatiana Chávez-Heres, Phaedra Silva-Bermudez, Rocio Aguilar-Gaytán, Natalia Manzano-León, Karla Méndez-Maldonado, Alejandro Alvarez-Arce, Raigam Jafet Martínez-Portilla
BMJ Open, doi:10.1136/bmjopen-2020-045190
New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial).
Competing interests None declared. Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. Patient consent for publication Not required. Ethics approval The approval of the research ethics committee of the INR-LGII of Mexico has been obtained. Provenance and peer review Not commissioned; externally peer reviewed. Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http:// creativecommons. org/ licenses/ by-nc/ 4. 0/. ORCID iD Julio Granados-Montiel http:// orcid. org/ 0000-0002-0611-6421
References
22 Geleris, Sun, Platt, Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2012410
Baig, Khaleeq, Ali, Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms, ACS Chem Neurosci, doi:10.1021/acschemneuro.0c00122
Chang, Sun, Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges, Drug Discov Today, doi:10.1016/j.drudis.2020.06.030
Chude, Amaravadi, Targeting autophagy in cancer: update on clinical trials and novel inhibitors, Int J Mol Sci, doi:10.3390/ijms18061279
Depfenhart, De Villiers, Lemperle, Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?, Intern Emerg Med, doi:10.1007/s11739-020-02383-3
Dm, COVID-19 dashboard México
Dutta, Sharma, Sharma, Short-Term hydroxychloroquine in COVID-19 infection in people with or without metabolic syndrome -clearing safety issues and good clinical practice, Eur Endocrinol, doi:10.17925/EE.2020.16.2.109
Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/bst.2020.01047
Guan, Ni, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Han, Ma, Li, Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors, Emerg Microbes Infect, doi:10.1080/22221751.2020.1770129
Helal, Gad, Mohamed Fahmy Abd-Ellah and Mse. hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in Genotype-4 chronic hepatitis C patients, Antivir Ther
Hoffmann, Kleine-Weber, Schroeder, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, doi:10.1016/j.cell.2020.02.052
Juurlink, Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection, CMAJ, doi:10.1503/cmaj.200528
Lai, Yu, Wang, Shorter incubation period is associated with severe disease progression in patients with COVID-19, Virulence, doi:10.1080/21505594.2020.1836894
Levy, Yagil, Bursztyn, Ace2 expression and activity are enhanced during pregnancy, Am J Physiol Regul Integr Comp Physiol, doi:10.1152/ajpregu.90592.2008
Li, Wang, Asymptomatic and human-to-human transmission of SARS-CoV-2 in a 2-Family cluster, Emerg Infect Dis, doi:10.3201/eid2607.200718
Luzzi, Peto, Adverse effects of antimalarials. An update, Drug Saf, doi:10.2165/00002018-199308040-00004
Mareev, Orlova, Pavlikova, Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial "BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT), Kardiologiia, doi:10.18087/cardio.2020.8.n1307
Paiardini, Müller-Trutwin, HIV-Associated chronic immune activation, Immunol Rev, doi:10.1111/imr.12079
Pal, Berhanu, Desalegn, Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2): an update, Cureus, doi:10.7759/cureus.7423
Ravi, Cortade, Ng, Diagnostics for SARS-CoV-2 detection: a comprehensive review of the FDA-EUA COVID-19 testing landscape, Biosensors and Bioelectronics, doi:10.1016/j.bios.2020.112454
Remuzzi, Remuzzi, COVID-19 and Italy: what next?, Lancet, doi:10.1016/S0140-6736(20)30627-9
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Wang, Lin, Huang, Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery, Journal of Interferon & Cytokine Research, doi:10.1089/jir.2014.0038
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China, JAMA, doi:10.1001/jama.2020.2648
Xu, Zhong, Deng, High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa, Int J Oral Sci, doi:10.1038/s41368-020-0074-x
Yao, Ye, Zhang, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis, doi:10.1093/cid/ciaa237
Zahr, Urien, Llopis, Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19, Therapie, doi:10.1016/j.therap.2021.01.056
Zanasi, Mazzolini, Kantar, A reappraisal of the mucoactive activity and clinical efficacy of bromhexine, Multidiscip Respir Med, doi:10.1186/s40248-017-0088-1
Zhan, Qin, Xue, Death from Covid-19 of 23 health care workers in China, N Engl J Med, doi:10.1056/NEJMc2005696
{ 'DOI': '10.1136/bmjopen-2020-045190', 'ISSN': ['2044-6055', '2044-6055'], 'URL': 'http://dx.doi.org/10.1136/bmjopen-2020-045190', 'abstract': '<jats:sec><jats:title>Introduction</jats:title><jats:p>SARS-CoV-2 infection in Mexico has ' 'caused ~2.7 million confirmed cases; around 20%–25% of health workers will be infected by the ' 'virus at their workplace, with approximately 4.4% of mortality. High infectivity of ' 'SARS-CoV-2 is related with cell entry mechanism, through the ACE receptor. SARS-CoV-2 ' 'requires transmembrane protease serine 2 to cleave its spike glycoprotein and ensure fusion ' 'of host cell and virus membrane. We propose studying prophylactic treatment with ' 'hydroxychloroquine (HCQ) and bromhexine (BHH), which have been shown to be effective in ' 'preventing SARS-CoV-2 infection progression when administered in early stages. The aim of ' 'this study is to assess the efficacy of HCQ and BHH as prophylactic treatments for SARS-CoV-2 ' 'infection in healthy health workers exposed to the ' 'virus.</jats:p></jats:sec><jats:sec><jats:title>Methods and ' 'analysis</jats:title><jats:p>Double-blind randomised clinical trial, with parallel allocation ' 'at a 1:1 ratio with placebo, of low doses of HCQ plus BHH, for 60 days. Study groups will be ' 'defined as follows: (1) HCQ 200 mg/day+BHH 8 mg/8 hours versus (2) HCQ placebo plus BHH ' 'placebo. Primary endpoint will be efficacy of both interventions for the prevention of ' 'SARS-CoV-2 infection, determined by the risk ratio of infected personnel and the absolute ' 'risk. At least a 16% reduction in absolute risk is expected between the intervention and ' 'placebo groups; a minimum of 20% infection is expected in the placebo group. The sample size ' 'calculation estimated a total of 214 patients assigned: two groups of 107 participants ' 'each.</jats:p></jats:sec><jats:sec><jats:title>Ethics and ' 'dissemination</jats:title><jats:p>This protocol has been approved by the local Medical Ethics ' 'Committee (National Institute of Rehabilitation ‘Luis Guillermo Ibarra Ibarra’, approval ' 'number INRLGII/25/20) and by the Federal Commission for Protection against Sanitary Risks ' '(COFEPRIS, approval number 203 300 410A0058/2020). The results of the study will be submitted ' 'for publication in peer-reviewed journals and disseminated through ' 'conferences.</jats:p></jats:sec><jats:sec><jats:title>Trial registration ' 'number</jats:title><jats:p><jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ' 'ext-link-type="clintrialgov" specific-use="clinicaltrial pre-results" ' 'xlink:href="NCT04340349">NCT04340349</jats:ext-link>.</jats:p></jats:sec>', 'alternative-id': ['10.1136/bmjopen-2020-045190'], 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-0611-6421', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Granados-Montiel', 'given': 'Julio', 'sequence': 'first'}, {'affiliation': [], 'family': 'Hazan-Lasri', 'given': 'Eric', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Franco-Cendejas', 'given': 'Rafael', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Chávez-Heres', 'given': 'Tatiana', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Silva-Bermudez', 'given': 'Phaedra', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Aguilar-Gaytán', 'given': 'Rocio', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Manzano-León', 'given': 'Natalia', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Méndez-Maldonado', 'given': 'Karla', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Alvarez-Arce', 'given': 'Alejandro', 'sequence': 'additional'}, { 'affiliation': [], 'family': 'Martínez-Portilla', 'given': 'Raigam Jafet', 'sequence': 'additional'}], 'clinical-trial-number': [ { 'clinical-trial-number': 'nct04340349', 'registry': '10.18810/clinical-trials-gov', 'type': 'preResults'}], 'container-title': 'BMJ Open', 'container-title-short': 'BMJ Open', 'content-domain': {'crossmark-restriction': True, 'domain': ['bmj.com']}, 'created': {'date-parts': [[2021, 8, 3]], 'date-time': '2021-08-03T16:33:23Z', 'timestamp': 1628008403000}, 'deposited': { 'date-parts': [[2021, 8, 3]], 'date-time': '2021-08-03T16:33:57Z', 'timestamp': 1628008437000}, 'funder': [ { 'award': ['SECTEI/061/2020'], 'name': 'Secretaría de Educación, Ciencia, Tecnologia e Inovacion de la Ciudad de México'}], 'indexed': {'date-parts': [[2022, 5, 17]], 'date-time': '2022-05-17T13:34:05Z', 'timestamp': 1652794445370}, 'is-referenced-by-count': 1, 'issue': '8', 'issued': {'date-parts': [[2021, 8]]}, 'journal-issue': { 'issue': '8', 'published-online': {'date-parts': [[2021, 8, 3]]}, 'published-print': {'date-parts': [[2021, 8]]}}, 'language': 'en', 'license': [ { 'URL': 'http://creativecommons.org/licenses/by-nc/4.0/', 'content-version': 'unspecified', 'delay-in-days': 2, 'start': { 'date-parts': [[2021, 8, 3]], 'date-time': '2021-08-03T00:00:00Z', 'timestamp': 1627948800000}}], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1136/bmjopen-2020-045190', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '239', 'original-title': [], 'page': 'e045190', 'prefix': '10.1136', 'published': {'date-parts': [[2021, 8]]}, 'published-online': {'date-parts': [[2021, 8, 3]]}, 'published-print': {'date-parts': [[2021, 8]]}, 'publisher': 'BMJ', 'reference': [ { 'key': '2021080308551899000_11.8.e045190.1', 'unstructured': 'C.DM . COVID-19 dashboard México 2021 ' 'https://covid19.who.int/region/amro/country/mx'}, { 'article-title': 'Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2): an update', 'author': 'Pal', 'first-page': 'e7423', 'journal-title': 'Cureus', 'key': '2021080308551899000_11.8.e045190.2', 'volume': '12', 'year': '2020'}, { 'DOI': '10.1080/21505594.2020.1836894', 'article-title': 'Shorter incubation period is associated with severe disease progression ' 'in patients with COVID-19', 'author': 'Lai', 'doi-asserted-by': 'crossref', 'first-page': '1443', 'journal-title': 'Virulence', 'key': '2021080308551899000_11.8.e045190.3', 'volume': '11', 'year': '2020'}, { 'DOI': '10.1056/NEJMoa2002032', 'doi-asserted-by': 'publisher', 'key': '2021080308551899000_11.8.e045190.4'}, { 'DOI': '10.3201/eid2607.200718', 'article-title': 'Asymptomatic and human-to-human transmission of SARS-CoV-2 in a ' '2-Family cluster, Xuzhou, China', 'author': 'Li', 'doi-asserted-by': 'crossref', 'first-page': '1626', 'journal-title': 'Emerg Infect Dis', 'key': '2021080308551899000_11.8.e045190.5', 'volume': '26', 'year': '2020'}, { 'DOI': '10.1038/s41368-020-0074-x', 'doi-asserted-by': 'crossref', 'key': '2021080308551899000_11.8.e045190.6', 'unstructured': 'Xu H , Zhong L , Deng J , et al . High expression of ACE2 receptor of ' '2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci ' '2020;12.doi:10.1038/s41368-020-0074-x'}, { 'DOI': '10.1152/ajpregu.90592.2008', 'doi-asserted-by': 'publisher', 'key': '2021080308551899000_11.8.e045190.7'}, { 'DOI': '10.1021/acschemneuro.0c00122', 'article-title': 'Evidence of the COVID-19 virus targeting the CNS: tissue distribution, ' 'host-virus interaction, and proposed neurotropic mechanisms', 'author': 'Baig', 'doi-asserted-by': 'crossref', 'first-page': '995', 'journal-title': 'ACS Chem Neurosci', 'key': '2021080308551899000_11.8.e045190.8', 'volume': '11', 'year': '2020'}, { 'DOI': '10.1056/NEJMc2005696', 'article-title': 'Death from Covid-19 of 23 health care workers in China', 'author': 'Zhan', 'doi-asserted-by': 'crossref', 'first-page': '2267', 'journal-title': 'N Engl J Med', 'key': '2021080308551899000_11.8.e045190.9', 'volume': '382', 'year': '2020'}, { 'DOI': '10.1001/jama.2020.2648', 'doi-asserted-by': 'publisher', 'key': '2021080308551899000_11.8.e045190.10'}, { 'DOI': '10.1016/S0140-6736(20)30627-9.', 'doi-asserted-by': 'publisher', 'key': '2021080308551899000_11.8.e045190.11'}, { 'DOI': '10.2165/00002018-199308040-00004', 'doi-asserted-by': 'publisher', 'key': '2021080308551899000_11.8.e045190.12'}, { 'DOI': '10.1089/jir.2014.0038', 'article-title': 'Hydroxychloroquine-inhibited dengue virus is associated with host ' 'defense machinery', 'author': 'Wang', 'doi-asserted-by': 'crossref', 'first-page': '143', 'journal-title': 'Journal of Interferon & Cytokine Research', 'key': '2021080308551899000_11.8.e045190.13', 'volume': '35', 'year': '2015'}, { 'article-title': 'Mohamed Fahmy Abd-Ellah and Mse. hydroxychloroquine augments early ' 'virological response to pegylated interferon plus ribavirin in ' 'Genotype-4 chronic hepatitis C patients', 'author': 'Helal', 'first-page': '52', 'journal-title': 'Antivir Ther', 'key': '2021080308551899000_11.8.e045190.14', 'volume': '55', 'year': '2006'}, { 'DOI': '10.1038/s41422-020-0282-0', 'doi-asserted-by': 'publisher', 'key': '2021080308551899000_11.8.e045190.15'}, { 'DOI': '10.5582/bst.2020.01047', 'doi-asserted-by': 'publisher', 'key': '2021080308551899000_11.8.e045190.16'}, { 'DOI': '10.1093/cid/ciaa237', 'article-title': 'In vitro antiviral activity and projection of optimized dosing design ' 'of hydroxychloroquine for the treatment of severe acute respiratory ' 'syndrome coronavirus 2 (SARS-CoV-2)', 'author': 'Yao', 'doi-asserted-by': 'crossref', 'first-page': '732', 'journal-title': 'Clin Infect Dis', 'key': '2021080308551899000_11.8.e045190.17', 'volume': '71', 'year': '2020'}, { 'DOI': '10.17925/EE.2020.16.2.109', 'article-title': 'Short-Term hydroxychloroquine in COVID-19 infection in people with or ' 'without metabolic syndrome – clearing safety issues and good clinical ' 'practice', 'author': 'Dutta', 'doi-asserted-by': 'crossref', 'first-page': '109', 'journal-title': 'Eur Endocrinol', 'key': '2021080308551899000_11.8.e045190.18', 'volume': '16', 'year': '2020'}, { 'DOI': '10.1080/22221751.2020.1770129', 'article-title': 'Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 ' 'are disease severity predictors', 'author': 'Han', 'doi-asserted-by': 'crossref', 'first-page': '1123', 'journal-title': 'Emerg Microbes Infect', 'key': '2021080308551899000_11.8.e045190.19', 'volume': '9', 'year': '2020'}, { 'DOI': '10.1111/imr.12079', 'doi-asserted-by': 'publisher', 'key': '2021080308551899000_11.8.e045190.20'}, { 'DOI': '10.3390/ijms18061279', 'article-title': 'Targeting autophagy in cancer: update on clinical trials and novel ' 'inhibitors', 'author': 'Chude', 'doi-asserted-by': 'crossref', 'journal-title': 'Int J Mol Sci', 'key': '2021080308551899000_11.8.e045190.21', 'volume': '18', 'year': '2017'}, { 'DOI': '10.1056/NEJMoa2012410', 'article-title': 'Observational study of hydroxychloroquine in hospitalized patients with ' 'Covid-19', 'author': 'Geleris', 'doi-asserted-by': 'crossref', 'first-page': '2411', 'journal-title': 'N Engl J Med', 'key': '2021080308551899000_11.8.e045190.22', 'volume': '382', 'year': '2020'}, { 'DOI': '10.1016/j.therap.2021.01.056', 'article-title': 'Pharmacokinetics and pharmacodynamics of hydroxychloroquine in ' 'hospitalized patients with COVID-19', 'author': 'Zahr', 'doi-asserted-by': 'crossref', 'journal-title': 'Therapie', 'key': '2021080308551899000_11.8.e045190.23', 'year': '2021'}, { 'DOI': '10.1016/j.drudis.2020.06.030', 'article-title': 'Repositioning chloroquine as antiviral prophylaxis against COVID-19: ' 'potential and challenges', 'author': 'Chang', 'doi-asserted-by': 'crossref', 'first-page': '1786', 'journal-title': 'Drug Discov Today', 'key': '2021080308551899000_11.8.e045190.24', 'volume': '25', 'year': '2020'}, { 'DOI': '10.1503/cmaj.200528', 'doi-asserted-by': 'publisher', 'key': '2021080308551899000_11.8.e045190.25'}, { 'DOI': '10.1186/s40248-017-0088-1', 'article-title': 'A reappraisal of the mucoactive activity and clinical efficacy of ' 'bromhexine', 'author': 'Zanasi', 'doi-asserted-by': 'crossref', 'first-page': '1', 'journal-title': 'Multidiscip Respir Med', 'key': '2021080308551899000_11.8.e045190.26', 'volume': '12', 'year': '2017'}, { 'DOI': '10.1007/s11739-020-02383-3', 'article-title': 'Potential new treatment strategies for COVID-19: is there a role for ' 'bromhexine as add-on therapy?', 'author': 'Depfenhart', 'doi-asserted-by': 'crossref', 'first-page': '801', 'journal-title': 'Intern Emerg Med', 'key': '2021080308551899000_11.8.e045190.27', 'volume': '15', 'year': '2020'}, { 'DOI': '10.1016/j.cell.2020.02.052', 'doi-asserted-by': 'publisher', 'key': '2021080308551899000_11.8.e045190.28'}, { 'article-title': 'Combination therapy at an early stage of the novel coronavirus ' 'infection (COVID-19). Case series and design of the clinical trial ' '“BromhexIne and Spironolactone for CoronаvirUs Infection requiring ' 'hospiTalization (BISCUIT)”', 'author': 'Mareev', 'first-page': '4', 'journal-title': 'Kardiologiia', 'key': '2021080308551899000_11.8.e045190.29', 'volume': '60', 'year': '2020'}, { 'DOI': '10.1016/j.bios.2020.112454', 'doi-asserted-by': 'publisher', 'key': '2021080308551899000_11.8.e045190.30'}], 'reference-count': 30, 'references-count': 30, 'relation': {}, 'resource': {'primary': {'URL': 'https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2020-045190'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['General Medicine'], 'subtitle': [], 'title': 'New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of ' 'hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE ' 'Trial)', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1136/crossmarkpolicy', 'volume': '11'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit